Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

被引：0
|
作者：
Xuetian Gao
Ling Peng
Li Zhang
Kai Huang
Cuihua Yi
Bei Li
Xue Meng
Jisheng Li
机构：
[1] Shandong Cancer Hospital and Institute,Department of Radiation Oncology
[2] Shandong First Medical University and Shandong Academy of Medical Science,Department of Respiratory Disease
[3] Zhejiang Provincial People’s Hospital,Department of Oncology
[4] Yunyang County People’s Hospital,Department of Medical Oncology
[5] Qilu Hospital,undefined
[6] Cheeloo College of Medicine,undefined
[7] Shandong University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
Anlotinib; Small cell lung cancer; Efficacy; Survival; Adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2661 / 2671
页数：10
相关论文
共 50 条
  • [41] The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
    Zheng, Hao-Ran
    Jiang, Ai-Min
    Gao, Huan
    Liu, Na
    Zheng, Xiao-Qiang
    Fu, Xiao
    Ruan, Zhi-Ping
    Tian, Tao
    Liang, Xuan
    Yao, Yu
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer (vol 15, pg 161, 2010)
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Nakamura, Yukiko
    Tsuya, Asuka
    Kaira, Kyoichi
    Igawa, Satoshi
    Shukuya, Takehito
    Tamiya, Akihiro
    Kaira, Rieko
    Endo, Masahiro
    Yamamoto, Nobuyuki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (03) : 331 - 331
  • [43] Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
    Qing Chen
    Yan Li
    Wenjie Zhang
    Chen Wang
    Shengjie Yang
    Qisen Guo
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 401 - 408
  • [44] Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
    Chen, Qing
    Li, Yan
    Zhang, Wenjie
    Wang, Chen
    Yang, Shengjie
    Guo, Qisen
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (02) : 401 - 408
  • [45] Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study
    Ding, Xiaomin
    Liu, Yuan
    Zhang, YaWen
    Liang, Jinrong
    Li, Qian
    Hu, Haiyan
    Zhou, Yan
    [J]. ANTI-CANCER DRUGS, 2023, 34 (07) : 877 - 882
  • [46] The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis
    Xu, Huilin
    Cao, Dedong
    Jie, Fangfang
    He, Anbing
    Ge, Wei
    [J]. TUMORI JOURNAL, 2023, 109 (02): : 203 - 214
  • [47] Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial (vol 9, pg 2621, 2020)
    Cheng, Ying
    [J]. CANCER MEDICINE, 2021, 10 (07): : 2523 - 2525
  • [48] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Shang, X. Q.
    Wang, T.
    Chen, G.
    Ma, C.
    Wang, H.
    Jia, X.
    Mei, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [49] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Wang, Q.
    Ma, C.
    Wang, T.
    Chen, G.
    Wang, H.
    Mei, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
  • [50] Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy
    Asai, Nobuhiro
    Ohkuni, Yoshihiro
    Matsunuma, Ryo
    Nakashima, Kei
    Iwasaki, Takuya
    Kaneko, Norihiro
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 266 - 271
12345